TY - JOUR
T1 - A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography
AU - Al'Aref, Subhi J.
AU - Su, Amanda
AU - Gransar, Heidi
AU - van Rosendael, Alexander R.
AU - Rizvi, Asim
AU - Berman, Daniel S.
AU - Callister, Tracy Q.
AU - DeLago, Augustin
AU - Hadamitzky, Martin
AU - Hausleiter, Joerg
AU - Al-Mallah, Mouaz H.
AU - Budoff, Matthew J.
AU - Kaufmann, Philipp A.
AU - Raff, Gilbert L.
AU - Chinnaiyan, Kavitha
AU - Cademartiri, Filippo
AU - Maffei, Erica
AU - Villines, Todd C.
AU - Kim, Yong Jin
AU - Leipsic, Jonathon
AU - Feuchtner, Gudrun
AU - Pontone, Gianluca
AU - Andreini, Daniele
AU - Marques, Hugo
AU - de Araújo Gonçalves, Pedro
AU - Rubinshtein, Ronen
AU - Achenbach, Stephan
AU - Chang, Hyuk Jae
AU - Chow, Benjamin J.W.
AU - Cury, Ricardo
AU - Lu, Yao
AU - Bax, Jeroen J.
AU - Jones, Erica C.
AU - Peña, Jessica M.
AU - Shaw, Leslee J.
AU - Min, James K.
AU - Lin, Fay Y.
N1 - Publisher Copyright:
© 2019
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Introduction: Non-statin therapy (NST)is used as second-line treatment when statin monotherapy is inadequate or poorly tolerated. Objective: To determine the association of NST with plaque composition, alone or in combination with statins, in patients undergoing coronary computed tomography angiography (coronary CTA). Methods: From the multicenter CONFIRM registry, we analyzed individuals who underwent coronary CTA with known lipid-lowering therapy status and without prior coronary artery disease at baseline. We created a propensity score for being on NST, followed by stepwise multivariate linear regression, adjusting for the propensity score as well as risk factors, to determine the association between NST and the number of coronary artery segments with each plaque type (non-calcified (NCP), partially calcified (PCP)or calcified (CP))and segment stenosis score (SSS). Results: Of the 27,125 subjects in CONFIRM, 4,945 met the inclusion criteria; 371 (7.5%)took NST. At baseline, patients on NST had more prevalent risk factors and were more likely to be on concomitant cardiac medications. After multivariate and propensity score adjustment, NST was not associated with plaque composition: NCP (0.07 increase, 95% CI: −0.05, 0.20; p = 0.26), PCP (0.10 increase, 95% CI: −0.10, 0.31; p = 0.33), CP (0.18 increase, 95% CI: −0.10, 0.46; p = 0.21)or SSS (0.45 increase, 95% CI: −0.02,0.93; p = 0.06). The absence of an effect of NST on plaque type was not modified by statin use (p for interaction > 0.05 for all). Conclusion: In this cross-sectional study, non-statin therapy was not associated with differences in plaque composition as assessed by coronary CTA.
AB - Introduction: Non-statin therapy (NST)is used as second-line treatment when statin monotherapy is inadequate or poorly tolerated. Objective: To determine the association of NST with plaque composition, alone or in combination with statins, in patients undergoing coronary computed tomography angiography (coronary CTA). Methods: From the multicenter CONFIRM registry, we analyzed individuals who underwent coronary CTA with known lipid-lowering therapy status and without prior coronary artery disease at baseline. We created a propensity score for being on NST, followed by stepwise multivariate linear regression, adjusting for the propensity score as well as risk factors, to determine the association between NST and the number of coronary artery segments with each plaque type (non-calcified (NCP), partially calcified (PCP)or calcified (CP))and segment stenosis score (SSS). Results: Of the 27,125 subjects in CONFIRM, 4,945 met the inclusion criteria; 371 (7.5%)took NST. At baseline, patients on NST had more prevalent risk factors and were more likely to be on concomitant cardiac medications. After multivariate and propensity score adjustment, NST was not associated with plaque composition: NCP (0.07 increase, 95% CI: −0.05, 0.20; p = 0.26), PCP (0.10 increase, 95% CI: −0.10, 0.31; p = 0.33), CP (0.18 increase, 95% CI: −0.10, 0.46; p = 0.21)or SSS (0.45 increase, 95% CI: −0.02,0.93; p = 0.06). The absence of an effect of NST on plaque type was not modified by statin use (p for interaction > 0.05 for all). Conclusion: In this cross-sectional study, non-statin therapy was not associated with differences in plaque composition as assessed by coronary CTA.
KW - Coronary computed tomography angiography
KW - Coronary plaque composition
KW - Ezetimibe
KW - Fibrate
KW - Niacin
KW - Non-statin therapy
UR - http://www.scopus.com/inward/record.url?scp=85061129457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061129457&partnerID=8YFLogxK
U2 - 10.1016/j.jcct.2019.01.015
DO - 10.1016/j.jcct.2019.01.015
M3 - Article
C2 - 30745132
AN - SCOPUS:85061129457
SN - 1934-5925
VL - 13
SP - 99
EP - 104
JO - Journal of cardiovascular computed tomography
JF - Journal of cardiovascular computed tomography
IS - 2
ER -